Comprehensive antibiotic susceptibility profiling of Chilean Piscirickettsia salmonis field isolates

• Published in: Journal of fish diseases Vol. 39; no. 4; pp. 441 - 448
• Main Authors: Henríquez, P, Kaiser, M, Bohle, H, Bustos, P, Mancilla, M
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.04.2016
• Subjects: Animals; Anti-Bacterial Agents - pharmacology; antibiotic resistance; Chile; Drug Resistance, Bacterial; Fish Diseases - microbiology; Fishes - microbiology; florfenicol; Microbial Sensitivity Tests; minimal inhibitory concentration; oxytetracycline; Piscirickettsia - drug effects; Piscirickettsia - isolation & purification; Piscirickettsia salmonis; Piscirickettsiaceae Infections - microbiology; Piscirickettsiaceae Infections - veterinary; Salmonidae; Chile; Piscirickettsia salmonis; minimal inhibitory concentration; oxytetracycline; florfenicol; antibiotic resistance
• ISSN: 0140-7775; 1365-2761
• DOI: 10.1111/jfd.12427

Antibiotics have been extensively used against infections produced by Piscirickettsia salmonis, a fish pathogen and causative agent of piscirickettsiosis and one of the major concerns for the Chilean salmon industry. Therefore, the emergence of resistant phenotypes is to be expected. With the aim of obtaining a landscape of the antimicrobial resistance of P. salmonis in Chile, the susceptibility profiles for quinolones, florfenicol and oxytetracycline (OTC) of 292 field isolates derived from main rearing areas, different hosts and collected over 5 years were assessed. The results allowed for the determination of epidemiological cut‐off values that were used to characterize the pathogen population. This work represents the first large‐scale field study addressing the antimicrobial susceptibility of P. salmonis, providing evidence of the existence of resistant types with a high incidence of resistance to quinolones. Remarkably, despite the amounts and frequency of therapies, our results disclosed that the issue of resistance to florfenicol and OTC is still in the onset.